Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?
- PMID: 21037434
- DOI: 10.1097/SLA.0b013e3181fc7f86
Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?
Abstract
Objective: Aim of this study was to evaluate whether delayed surgery after neoadjuvant chemoradiotherapy (CRT) affects postoperative outcomes in patients with locally advanced squamous cell carcinoma (SCC) of the thoracic esophagus.
Background: Esophagectomy is usually recommended within 4 to 6 weeks after completion of neoadjuvant CRT. However, the optimal timing of surgery is not clearly defined.
Methods: A total of 129 consecutive patients with locally advanced esophageal cancer, treated between 1998 and 2007, were retrospectively analyzed using prospectively collected data. Patients were divided into 3 groups on the basis of timing to surgery: group 1, ≤30 days (n = 17); group 2, 31 to 60 days (n = 83); and group 3, 61 to 90 days (n = 29). Subsequently, only 2-numerically more consistent-groups were studied, using the median value of timing intervals as a cutoff level: group A, ≤46 days (n = 66); and group B, >46 days (n = 63).
Results: Groups were comparable in terms of patient and tumor characteristics, type of neoadjuvant regimen, toxicity, postoperative morbidity and mortality rates, tumor downstaging, and pathologic complete responses. The overall 5-year actuarial survival rate was 0% in group 1, 43.1% in group 2, and 35.9% in group 3 (P = 0.13). After R0 resection (n = 106), the 5-year actuarial survival rate was 0%, 51%, and 47.3%, respectively (P = 0.18). Tumor recurrence after R0 resection seemed to be inversely related, even if not significantly (P = 0.17), to the time interval between chemoradiation and surgery: 50% in group 1, 40.6% in group 2, and 21.7% in group 3. When considering only 2 groups, the overall 5-year survival was 33.1% in group A and 42.7% in group B (P = 0.64); after R0 resection, the 5-year survival was 37.8% and 56.3%, respectively (P = 0.18). The rate of tumor recurrence was significantly lower in group B (25%) than in group A (48.3%) (P = 0.02).
Conclusion: Delayed surgery after neoadjuvant chemoradiation does not compromise the outcomes of patients with locally advanced SCC of the esophagus. Delaying surgery up to 90 days offers relevant advantages in the clinical management of the patients, can reduce tumor recurrences, and may improve prognosis after complete R0 resection surgery.
Comment in
-
Surgery: Delays may improve outcomes.Nat Rev Clin Oncol. 2011 Feb;8(2):62. doi: 10.1038/nrclinonc.2010.214. Nat Rev Clin Oncol. 2011. PMID: 21360840 No abstract available.
Similar articles
-
REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.Ann Surg Oncol. 2006 Dec;13(12):1724-31. doi: 10.1245/s10434-006-9075-z. Epub 2006 Sep 30. Ann Surg Oncol. 2006. PMID: 17009160
-
Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report.Oncol Rep. 2005 Nov;14(5):1177-82. Oncol Rep. 2005. PMID: 16211282 Clinical Trial.
-
Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):348-56. doi: 10.1016/j.ijrobp.2009.02.086. Int J Radiat Oncol Biol Phys. 2009. PMID: 19735862
-
[New trends in neoadjuvant chemoradiotherapy for locally-advanced esophageal cancer: esophagectomy--is it necessary?].Gan To Kagaku Ryoho. 2000 Nov;27(13):2016-22. Gan To Kagaku Ryoho. 2000. PMID: 11103231 Review. Japanese.
-
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.Ann Thorac Surg. 2004 Oct;78(4):1177-83. doi: 10.1016/j.athoracsur.2004.02.068. Ann Thorac Surg. 2004. PMID: 15464466 Review.
Cited by
-
Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.World J Gastroenterol. 2018 Jan 14;24(2):257-265. doi: 10.3748/wjg.v24.i2.257. World J Gastroenterol. 2018. PMID: 29375211 Free PMC article.
-
Timing After Neoadjuvant Therapy Predicts Mortality in Patients Undergoing Esophagectomy: a Propensity Score-Matched Analysis.J Gastrointest Surg. 2023 Nov;27(11):2342-2351. doi: 10.1007/s11605-023-05851-1. Epub 2023 Oct 17. J Gastrointest Surg. 2023. PMID: 37848687
-
Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):195-203. doi: 10.1016/j.ijrobp.2013.09.037. Epub 2013 Nov 1. Int J Radiat Oncol Biol Phys. 2014. PMID: 24189128 Free PMC article.
-
Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma.BMC Gastroenterol. 2025 Apr 4;25(1):223. doi: 10.1186/s12876-025-03802-5. BMC Gastroenterol. 2025. PMID: 40186133 Free PMC article.
-
Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer.Ann Surg Oncol. 2019 Dec;26(13):4765-4772. doi: 10.1245/s10434-019-07779-w. Epub 2019 Oct 16. Ann Surg Oncol. 2019. PMID: 31620943 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials